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Abstract
Background: BCMA (B-cell maturation) belongs to the tumour necrosis factor receptor gene
family, and is specifically expressed in mature B lymphocytes. Antisense BCMA RNA is produced
by transcription from the same locus and has typical mRNA features, e.g, polyadenylation, splicing,
Kozak consensus sequence and an ORF (p12). To investigate the function of antisense BCMA RNA,
we expressed BCMA in cell lines, in the presence of antisense p12 or a mutant lacking the initiation
ATG codon (p12-ATG).
Results: Overexpression of both p12 and p12-ATG antisense BCMA resulted in a large decrease
in the amount of BCMA protein produced, with no change in BCMA RNA levels, indicating that
BCMA expression is regulated by antisense BCMA RNA at the translational level. We have also
observed slight adenosine modifications, suggestive of the activity of a double-stranded RNA-
specific adenosine deaminase.
Conclusion: These data suggest that antisense BCMA may operate under physiological conditions
using similar antisense-mediated control mechanisms, to inhibit the expression of the BCMA gene.
Background
BCMA (B-cell maturation) belongs to the tumour necrosis
factor receptor (TNFR) gene family [1], and is specifically
expressed in mature B lymphocytes [2,3]. BCMA and TACI
(transmembrane activator and CAML-interactor), another
TNFR-homologue [4], bind two TNF-homologues; BAFF
(also called TALL-1, THANK, BLyS, and zTNF4) [5–9] and
APRIL [10]. Futhermore, BAFF can bind to a third receptor
BAFF-R which is specific to this ligand.[11,12]. This de-
fines a complexe ligand-receptor system that may play an
important role in B lymphocyte differentiation [9,13–18]
and in the regulation of B-cell function.
Naturally occurring antisense RNAs in eukaryotes may
regulate sense gene expression, acting at the transcription-
al, post-transcriptional or translational level [19]. We
have previously reported the presence of a natural anti-
sense BCMA RNA, which is produced by transcription
from the same locus as BCMA and has typical mRNA fea-
tures, e.g. polyadenylation, splicing, Kozak consensus se-
Published: 18 April 2002
BMC Molecular Biology 2002, 3:4
Received: 9 January 2002
Accepted: 18 April 2002
This article is available from: http://www.biomedcentral.com/1471-2199/3/4
© 2002 Hatzoglou et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, 
provided this notice is preserved along with the article's original URL.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/4
Page 2 of 7
(page number not for citation purposes)
quence and an open reading frame encoding a 115 amino
acid peptide (p12) [20]. RNase protection assays demon-
strated the simultaneous presence of natural sense and an-
tisense BCMA transcripts in most of the human B-cell
lines and lymphoid tissues tested. We have not succeded
to evidence antisense-BCMA transcripts in mouse B lym-
phocytes. In this study, we investigated whether antisense
BCMA RNA regulated the expression of sense BCMA. We
observed an inhibition of BCMA expression, the extent of
inhibition increasing with the amount of antisense BCMA
RNA. This regulation took place at the translational level.
These data suggest that similar antisense RNA-mediated
control mechanisms may operate in the control of BCMA
expression in differenciating primary B lymphocytes.
Results and Discussion
BCMA overexpression, like that of all TNFRs described to
date, activates the NF-kappaB nuclear factor [21]. To in-
vestigate the function of antisense BCMA p12, we overex-
pressed BCMA in transient expression experiments, in 293
cells. We investigated whether the simultaneous expres-
sion of BCMA and p12 altered the activation of NF-kap-
paB from that observed if cells were transfected with
BCMA alone. Overexpression of the antisense p12 con-
struct resulted in no activation of NF-kappaB, observed
with the insert-less vector. Overexpression of human
BCMA induced the activation of NF-kappaB, to a level 11
times higher than that observed with the insert-less vector.
This activation level was in the same range as that ob-
served (16-fold) with LMP1, a known activator of this nu-
clear factor [22]. Co-transfection with hBCMA and p12
constructs led to a decrease by more than 50% in NF-kap-
paB activation. Co-transfection with LMP1 and p12 con-
structs did not result in lower levels of activation of NF-
kappaB than addition of LMP1 alone. In transient co-
transfection experiments (Fig. 1), antisense p12 specifical-
ly inhibited the activation of NF-kappaB obtained by
overexpression of BCMA alone.
We then investigated whether the p12 protein or the cor-
responding RNA was responsible for the observed inhibi-
tion of NF-kappaB activation. We constructed a pcDNA3
vector encoding the p12 sequence, but without the ATG
initiation codon (p12-ATG). We assayed NF-kappaB acti-
vation, when N-terminal FLAG-tagged BCMA (FhBCMA)
was overexpressed in the presence of various amounts of
constructs expressing either p12 or p12-ATG. We found
(Fig. 2A) that p12 and p12-ATG inhibited NF-kappaB ac-
tivation similarly, in a dose-dependent manner. The addi-
tion of neither p12 nor p12-ATG, in 7.5-fold excess, did
not affect the NF-kappaB activation obtained by overex-
pressing LMP1 (Fig. 2C), indicating that the observed de-
crease in activation (Fig. 2A) was specific for BCMA. These
data indicate that the antisense p12 RNA and not the p12
protein is responsible for the observed inhibition of NF-
kappaB activation. We also tested, in the same experi-
ment, whether the amount of BCMA protein produced de-
pended directly on the amount of antisense construct
added. Western blotting of 20 µg of each sample (Fig. 2B)
demonstrated that the addition of increasing amounts of
either the p12 or the p12-ATG construct decreased to a
Figure 1
Overexpression of natural antisense BCMA
decreases BCMA-mediated NF-kappaB activation.
293 cells were co-transfected with a total of 1 µg of various
plasmids. All samples contained 100 ng of the luciferase
reporter plasmid and 50 ng of pGKβ -gal plasmid. The nega-
tive control value was obtained the insert-less pcDNA3 vec-
tor (vector). NF-kappaB activation was measured in samples
transfected with a) 100 ng of pcDNA3aSp12 (p12), b) 100 ng
of pcDNA3LMP1 (LMP1), c) 100 ng each of LMP1 and p12
(LMP1+p12), d) 100 ng of pcDNA3hBCMA (hBCMA) and e)
100 ng each of hBCMA and p12 (hBCMA+p12). The quantity
of plasmid added was adjusted to 1 µg by adding sufficient
insert-less pcDNA3 vector. 18–24 h after transfection, cells
were harvested, lysed and analysed for luciferase and β -galac-
tosidase activity. Luciferase values were normalised to β -
galactosidase activity and the results are displayed as a multi-
ple of the induction by vector alone. A representative result
of three independent experiments is shown. Error bars
denote standard deviations for triplicate samples.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/4
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similar extent the amount of BCMA protein. BCMA pro-
tein was not detected if a 7.5-fold excess of any antisense
construct was added.
Antisense RNAs may regulate expression of the corre-
sponding sense genes, at the nuclear, transcriptional, post-
transcriptional or translational level [19]. To determine
the level at which antisense BCMA acts, we studied the lev-
els of BCMA mRNA and BCMA protein in 293T cells tran-
siently transfected with FLAG-tagged hBCMA, in the
presence of various concentrations of antisense p12-ATG
construct. Cells were harvested and the resulting cell sus-
pension was split in two. One half was lysed, soluble pro-
tein concentration determined and equal amounts of
protein per lane were subjected to electrophoresis and
Western immunoblotting, using M2 anti-FLAG mAb. The
other half of the cell suspension was used to prepare total
RNA. Northern blot experiments were performed to check
the levels of hBCMA and human β -actin mRNA (control).
We found that production of BCMA protein was inhibited
by the addition of antisense BCMA (Fig. 3). In the condi-
tions used, BCMA protein production was abolished, if a
nine-fold excess of antisense construct was added. The
Northern blot results clearly indicate that the level of
BCMA mRNA is stable and unaffected by the addition of
increasing amounts of antisense BCMA expression vector.
The level of β -actin mRNA is shown as a control. These
data clearly indicate that antisense BCMA RNA does not
affect the transcription of BCMA to give sense mRNA. In
contrast, BCMA protein production is inhibited.
We have measured by RNase protection assay the level of
BCMA and antisense BCMA gene expression in some B
lymphocytes cell lines in order to assess the relative pro-
portion of each RNA in these cell lines. The results ob-
tained show that antisense and sense RNAs are present
simultaneously in Daudi, RPMI 8226, Raji and 167 cell
lines; REH6 contains only antisense, while JEA contains
only sense transcripts (Fig 4). These results did not show
any rational correlation of the expressed amounts of sense
and antisense-BCMA transcripts and indicate that each
gene seems to be trancribed in an independent way. It has
been reported that antisense RNA may cause the nuclear
retention of sense RNA and the modification of adenos-
ines to inosines in the sense-antisense hybrid double-
stranded RNA, by the enzyme double-stranded RNA-spe-
cific adenosine deaminase (dsRAD/DRADA) [23,24]. This
enzyme is present in the nucleus of somatic cells, has un-
winding and modifying activity and is ubiquitous. We in-
vestigated whether this editing phenomenon occurred in
the sense-antisense BCMA interaction by isolating cyto-
plasmic and nuclear total RNA from 293 cells transiently
transfected with hBCMA in the presence or absence of a
five-fold excess of antisense p12-ATG expression vector.
The RNA was reverse-transcribed and PCR performed with
Figure 2
Expression of antisense RNA is sufficient to obtain
inhibition.A. 293T cells were co-transfected with a total of
1 µg of various plasmids, using the same conditions for meas-
uring NF-kappaB activation as in Fig. 1. The negative control
was insert-less SV40 promoter-driven pSG5FLAG vector
(vector). All other samples were transfected with 100 ng of
pSG5FLAGhBCMA (FhBCMA) vector and various amounts
of pcDNA3aSp12 (p12) or pcDNA3aSp12-ATG (p12-ATG),
lacking the initiation ATG codon. Cells were harvested and
lysed 48 hours after transfection and the lysate was assayed
for NF-kappaB activation. B. Lysate (20 µg) were subjected
to electrophoresis and the amount of FhBCMA in 293T cells
was determined by western blotting using the M2 anti-FLAG
monoclonal antibody. We checked that the amount of pro-
tein was similar in all samples of 293T cells by subjecting 10
µg of cell lysate to western blotting using a rabbit polyclonal
anti-PI3-Kp85 antibody. C. The positive control was trans-
fection with either 100 ng of LMP1 or 100 ng of LMP1 and
750 ng of p12 or p12-ATG expression vector.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/4
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Figure 3
Antisense BCMA RNA affects BCMA protein expres-
sion only on translational level. 293T cells were trans-
fected with insert-less vector or vector expressing FhBCMA
in the presence of various amounts of p12-ATG expression
vector. 48 hours after transfection cells were harvested and
the cell suspension split in two. One half (about 107 cells)
was lysed in appropriate buffer and 14 µg of the resulting cell
lysate was assayed by western blotting using the M2 anti-
FLAG monoclonal antibody to test for FhBCMA. We tested
that the protein levels were similar in the various samples by
western blotting using a rabbit polyclonal anti-actin antibody.
The other half of the cell suspension was used to prepare
total RNA, which was used for northern blot to assess
BCMA and human β -actin levels. 293T cells were transfected
with (A) none, (B) 1 µg of insert-less pcDNA3, (C) 100 ng
hBCMA, (D) 100 ng p12-ATG, (E) 100 ng hBCMA and 100 ng
p12-ATG, (F) 100 ng hBCMA and 900 ng p12-ATG. Except
for (A), cells were transfected with total of 1 µg of plasmid
using when needed insert-less pcDNA3.
Figure 4
RNase protection assay. RNase protection analysis of the
BCMA and antisense-BCMA gene transcription in human B
lymphocyte cell lines: RPMI 8226 (A), 167 (B), Daudi (C), Raji
(D), JEA (E) and REH (F). 10 (30) µg of total RNA were used
for the analysis of BCMA (antisense-BCMA) gene transcrip-
tion. Antisense results were obtained with 20-fold longer
exposure than that of sense.
Figure 5
A. Structure of the BCMA gene and its correspond-
ing antisense mRNA. The exons are indicated by boxes
(white for the coding sequences and black for the 5' and 3'
untranslated exons). Arrows indicate the direction of tran-
scripton. The relative positions of the sense BCMA and anti-
sense p12 cDNAs are also shown and the location of the
restriction sites used indicated (M for XmnI, H for XhoI, R for
RsaI and S for SalI). B. Analysis of RT-PCR products.
293T cells were transfected with vector expressing FhBCMA
in the presence of a five-fold excess of p12-ATG expression
vector. 48 hours after transfection, cells were harvested and
cytoplasmic and nuclear RNA isolated, reverse transcribed
and amplified by PCR . The resulting 555 bp BCMA band was
digested with XmnI, and XhoI restriction enzymes. The
results of these digestions are shown. C. Sequence com-
parison of clone #10 with that of WT human BCMA
cDNA. Only the sequence overlapping the antisense BCMA
is shown (modifications were found only in this part of the
sequence). Only modified bases are indicated in the sequence
of the #10 clone. Other sequences were identical. The XmnI,
XhoI, RsaI and SalI sites are underlined.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/4
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specific oligonucleotide primers to amplify the entire cod-
ing sequence of BCMA. These priners have been chosen
outside the overlapping zone between sense and anti-
sense-BCMA, in which editing can only be observed: (5'-
CGGGATCCGCTGGGCAGTGCTCCCAAA-3'; 5'-
CCCAAGCTTTTACCTAGCAGAAATTGATTTC-3'). The re-
sulting 555 bp fragment was digested with RsaI, XhoI, SalI
and XmnI, all of which have unique restriction sites in
BCMA cDNA (Fig. 5A), to verify whether there had been
any modification of the adenosines of these restriction
sites. The results obtained for XmnI and XhoI digestion are
presented in Fig. 5B. Amplified sequences of cytoplasmic
and nuclear origin were totally digested, giving rise to two
bands of 333 and 222 bp for XmnI and 354 and 201 bp
for XhoI digestion. Similar results were obtained with RsaI
and SalI restriction enzymes (data not shown). Thus there
was no significant modification of the adenosines present
in the restriction sites for these enzymes. Although we ob-
tained no evidence for extensive adenosine modification,
we digested the 555 bp band, amplified from nuclear cD-
NA, with BamHI and HindIII, inserted it between the Bam-
HI and HindIII sites of pUC18 and sequenced 29 clones.
Twenty-eight of these clones had sequences identical to
that of WT BCMA. Only one clone (#10) displayed modi-
fications to 18% of adenosines (converted to guanosines),
with no modification of any other base, indicating a slight
RNA editing effect in the presence of BCMA antisense
RNA (Fig. 5C). These modifications may be attributed to
the action of the dsRAD/DRADA enzyme and indicate
that BCMA sense expression is regulated by antisense RNA
at more than one level. These observations are consistent
with the results obtained in a previous paper [20], in
which no editing had been observed on 11 sequenced an-
tisense-BCMA cDNAs. These results suggest that if there is
any modification, it must be rare.
BAFF-R, BCMA and TACI receptors are present on B lym-
phocytes. BAFF-R binds only BAFF, while BCMA and TACI
bind with slight differences in affinity to the same ligands,
BAFF and APRIL [13,15]. Their patterns of signal transduc-
tion differ [21,25], indicating that they may be responsi-
ble for different fates of differentiating B lymphocytes.
Several mechanisms of control of expression of either one
of these receptors may be used by the cell, resulting in dif-
ferent differentiation pathways for B lymphocytes (mem-
ory cells, germinal centre cells and/or plasmocytes). In
this paper, we present evidence, that in transient expres-
sion experiments, BCMA gene expression is tightly and
rapidly regulated by antisense BCMA RNA.
Conclusions
The data obtained from the transient expression experi-
ments suggest that antisense BCMA inhibits the expres-
sion of BCMA protein and does not affect the expression
level of BCMA mRNA. The use of a vector missing the in-
itiation codon for the putative antisense p12 protein
showed that the inhibition of the BCMA protein expres-
sion is obtained through the action of the antisense RNA
and not of the p12 protein. These data suggest that anti-
sense BCMA may operate under physiological conditions
using similar antisense-mediated control mechanisms, to
inhibit the expression of the BCMA gene
Materials and Methods
RNA isolation
Nuclear and cytoplasmic RNAs were isolated by a method
described elsewhere [26]. Total RNA was isolated using
the TRIzol reagent (Life Technologies, Grand Island, NY)
and reverse transcribed using the "Superscript preamplifi-
cation system" (Life Technologies, Grand Island, NY).
Northern blot analysis
20 µg of total RNA per lane were electrophoresed in a 1%
agarose gel, transferred onto Nylon filter (Amersham) and
hybridized, as previously described [27]. Probes (human
BCMA and β -actin full-lentgh cDNAs) were labelled, us-
ing the random prime method [28]. 32P-labelled nucle-
otides were purchased from Amersham.
Antibodies and reagents
M2 anti-FLAG monoclonal antibody and protease inhibi-
tors were purchased from Sigma-Aldrich. Goat anti-
mouse IgG polyclonal antibodies HRP-conjugated and
donkey anti-rabbit IgG polyclonal antibodies HRP-conju-
gated were purchased from Immunotech, Marseille,
France. Rabbit polyclonal anti-PI3-K p85 antibodies were
from UPI, Lake Placid, NY. Rabbit polyclonal anti-actin
antibodies were from Sigma Aldrich. DMEM, fetal calf se-
rum, additional reagents for cell culture, Optimem and
Lipofectamine were purchased from Life Technologies.
Primers
BCMA 5'ATG (5'-AAGCTTATGTTGCAGATGGCTGGGCA-
3')
BCMA 3'TAA (5'-GGATCCTTACCTAGCAGAAATTGATT-
TC-3')
AH7 (CGCGGATCCTTACCTAGCAGAAATTGATTTCT-3')
BFL1 (5'-AACTGCAGCTGGGCAGTGCTCCCAAAA-3')
p12 5' (5'-AAGCTTATGGTTGCGCCTTCCTCCAT-3')
p12 3' (5'-GGATCCTTATTGTAATGCAAGTGTGACCA-3')
p12-ATG 5' (5'-GGAATTCGTTGCGCCTTCCTCCATAG-
3')BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/4
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p12-ATG 3' (5'-TCTAGATTATTGTAATGCAAGTGTGAC-
CA-3')
All primers used in this study were purchased from
Genset, Paris, France.
Expression vectors
A full length human BCMA (h184) was amplified by PCR
from human cDNA, using the BCMA5'ATG and
BCMA3'TAA primers. The PCR fragment was digested
with BamHI and HindIII restriction enzymes and ligated
into the BamHI and HindIII sites of the vector pcDNA3
(Invitrogen, The Netherlands).
N-terminal FLAG-tagged human BCMA was constructed
by PCR amplification using the BFL1 and AH7 pair of
primers. The PCR product was digested with PstI and
BamHI and ligated between the PstI and BamHI sites of
the vector pSG5-FLAG [29].
A full length p12 was amplified by PCR from human cD-
NA, using the p12 5' and p12 3' pair of primers. The PCR
product was digested with HindIII and BamHI restriction
enzymes and ligated between the HindIII and BamHI sites
of the vector pcDNA3. A mutant lacking the initiation
ATG codon (p12-ATG) was amplified by PCR from hu-
man BCMA cDNA using the p12-ATG 5' and p12-ATG 3'
pair of oligonucleotide primers. The PCR fragment was di-
gested with EcoRI and XbaI restriction enzymes and was
ligated between the EcoRI and XbaI sites of the vector
pcDNA3.
All expression vectors were constructed by standard re-
combinant DNA procedures. The sequence of the plas-
mids constructed by PCR amplification were
subsequently verified by dideoxy sequencing (Génome
Express, Montreuil, France).
The vectors pcLMP1 [30] and the β -galactosidase expres-
sion vector (pGKβ gal), in which expression is driven by
the phosphoglucokinase promoter [29] have been already
described.
Cell lines and transfections
Human B-lymphocyte cell lines included the precursor
REH6 and JEA [31], the mature Daudi, Raji and the 167
EBV-transformed B lymphoblastoid cell line (obtained
from normal cells in the lab) and the myeloma RPMI
8226 cell line. Human embryonic kidney 293 and 293T
cells, were maintained in high glucose Dulbecco's modi-
fied Eagle's medium (DMEM), supplemented with 10%
heat-inactivated fetal calf serum, 2 mM glutamine, 100 U/
ml of penicillin and 100 µg/ml of streptomycin and were
grown at 37°C, in 5% CO2. Adherent cells were seeded in
six-well plates (5 ×  105 cells per well) in 2 ml of complete
medium, incubated at 37°C in 5% CO2 for 20–24 hours
and transfected with lipofectamine according to the man-
ufacturer's instructions, using 1 µg of total plasmid DNA,
for 6 hours.
Luciferase reporter system for NF-kappaB
The NF-kappaB activation assays were performed using
the corresponding luciferase reporter PathDetect Report-
ing system purchased from Stratagene (La Jolla, CA).
Luciferase and β -galactosidase assays
Transfected cells were washed twice with PBS and lysed
with Reporter lysis buffer (Promega, Madison, WI). The
luciferase activity was measured using the Reporter assay
system (Promega, Madison, WI). β -galactosidase activity
was measured using the Luminescent β -galactosidase re-
porter system (Clontech, Palo Alto, CA). Luminescence
was measured using a microplate (EG&G Berthold, Bad
Wildbad, Germany). Measurements of luciferase were
normalized to β -galactosidase activity and are expressed
as a ratio to values obtained from cells treated with vector
alone. The relative luciferase activities given are represent-
ative of triplicate assays in three independent experi-
ments.
Western blots
Adherent cells were washed with cold PBS and detached
using cold PBS containing 5 mM EDTA and then lysed in
lysis buffer (10 mM Tris, pH 7.6, 5 mM NaCl, 30 mM so-
dium pyrophosphate, 50 mM NaF, 400 µM orthovanad-
ate, 1 mM Pefabloc, 5 µg/ml aprotinin, 1 µg/ml pepstatin,
2 µg/ml leupeptin, 0.1% Triton X-100) by incubation for
1 h at 4°C and the supernatant was then clarified by cen-
trifugation. The lysates were analyzed by PAGE and trans-
fered onto PVDF membrane (HybondP, Amersham). The
presence of FLAG-tagged BCMA construct was evidenced
using M2 anti-FLAG antibody. Rabbit polyclonal anti-
PI3K antibody was used to detect the presence of PI3K and
rabbit polyclonal anti-actin antibody was used to detect
the presence of actin. HRP-conjugated anti-rabbit and
anti-mouse IgG and SuperSignal Chemiluminescent sub-
strate (Pierce) were used to reveal the blots.
RNase protection assay
RNase protection assay has been performed as previously
described [20].
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